Skip to content
Hikma
-
S&P Global upgrades Hikma Pharmaceuticals’ Credit Rating to ‘BBB’ on strong performance
This growth was fueled by the launch of over 100 new products, which helped offset margin pressures in the U.S. generics business due to increased royalty payments.
-
-
Hikma partners with Pharmaand to market Rucaparib in MENA
Rucaparib, sold under the brand name Rubraca®, is an innovative oral therapy that targets poly (ADP-ribose) polymerases (PARPs)—proteins essential for DNA repair in cancer cells.